Joseph Tom

“Maybe just in setting expectations in terms of when we should hear next steps on sort of the filing progress, I guess. What are you anticipating in terms of relaying kind of your FDA interactions to the street?”

“Maybe just as we're thinking about some of the other offerings, either the Rolentapeg and PAH for the Tresme and PAH and PHLD. I guess, how much do you think you're going to be able to kind of recapture maybe some of the momentum that you did lose by increased competition in the space?”

“For the FHCTU market, how would you see the difference in prescribing between the U.S. and European markets or any changes in practice guidelines between the two that we should be thinking about?”

“Maybe a little bit of an extension of a prior question, but can you walk through the physician touchpoint differences between CIC and IBS constipation? And I guess if you are successful in CIC, would you need to go a little bit more maybe into a primary care segment or anything like that with your sales force?”

“And maybe one on the upcoming PSC trial, our CAROWELLs are hinting that maybe the itch associated with in PSC patients can be a little bit more episodic. Maybe do you see that as providing a little bit more risk into this study versus what you're seeing in PBC?”